Trials / Unknown
UnknownNCT04073550
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
A Randomized, Double-Blind, Multicenter, Phase Ⅲ Study of Anlotinib Hydrochloride Capsule Combined With Topotecan Versus Placebo Combined With Topotecan in Subjects With Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Anlotinib hydrochloride is a multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis-related kinases such as VEGFR1/2/3, FGFR1/2/3, and other tumor-associated kinases involved in cell proliferation such as PDGFRα/β, c-Kit, and Ret have significant inhibitory activities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | A multi-target receptor tyrosine kinase inhibitor. |
| DRUG | Placebos | Anlotinib blank analog capsule. |
| DRUG | Topotecan | A topoisomerase I inhibitor. |
Timeline
- Start date
- 2019-10-31
- Primary completion
- 2021-07-31
- Completion
- 2022-07-31
- First posted
- 2019-08-29
- Last updated
- 2019-08-29
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04073550. Inclusion in this directory is not an endorsement.